Stock SNPX SYNAPTOGENIX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Synaptogenix, Inc.

Equities

SNPX

US87167T3005

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-05-20 pm EDT 		5-day change 1st Jan Change
4.84 USD +1.89% Intraday chart for Synaptogenix, Inc. +7.08% -28.80%
Apr. 09 Synaptogenix, Inc. acquired Unknown Stake in Psyga Bio Ltd from Cannasoul Analytics Ltd. CI
Apr. 03 Synaptogenix Plans 1-for-25 Reverse Stock Split; Shares Fall MT

Valuation

Fiscal Period: December 2020 2021 2022 2023
Capitalization 1 7.545 56.8 8.43 5.544
Enterprise Value (EV) 1 1.75 22.59 -29.05 -24.56
P/E ratio -0.5 x -3.38 x -1.42 x -0.23 x
Yield - - - -
Capitalization / Revenue - - - -
EV / Revenue - - - -
EV / EBITDA -0.16 x -1.79 x 1.8 x 2.96 x
EV / FCF -429,295 x -5,661,727 x 4,621,761 x 57,491,953 x
FCF Yield -0% -0% 0% 0%
Price to Book 1.47 x 1.71 x 0.26 x 0.27 x
Nbr of stocks (in thousands) 50.3 267 291 816
Reference price 2 150.0 212.8 29.00 6.798
Announcement Date 3/30/21 3/29/22 3/21/23 4/1/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023
Net sales - - - - -
EBITDA 1 -15.51 -11.15 -12.61 -16.13 -8.308
EBIT 1 -15.51 -11.16 -12.62 -16.13 -8.314
Operating Margin - - - - -
Earnings before Tax (EBT) 1 -15.13 -12.7 -12.61 -5.574 -6.039
Net income 1 -15.13 -12.7 -12.61 -5.574 -6.039
Net margin - - - - -
EPS 2 -300.9 -300.8 -62.87 -20.35 -29.56
Free Cash Flow - -4.077 -3.989 -6.285 -0.4271
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 3/30/21 3/30/21 3/29/22 3/21/23 4/1/24
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1
Net sales 1 - - - - -
EBITDA - - - - -
EBIT 1 -3.283 -3.796 -3.167 -5.889 -2.922
Operating Margin - - - - -
Earnings before Tax (EBT) 1 -3.278 -3.752 -3.026 4.482 -1.712
Net income 1 -3.278 -3.752 -3.026 4.366 -1.978
Net margin - - - - -
EPS 2 -11.75 -13.50 -10.75 15.75 -6.500
Dividend per Share - - - - -
Announcement Date 5/13/22 8/5/22 11/10/22 3/21/23 5/15/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023
Net Debt 1 - - - - -
Net Cash position 1 17.4 5.8 34.2 37.5 30.1
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - -4.08 -3.99 -6.29 -0.43
ROE (net income / shareholders' equity) - -113% -65.2% -16.2% -19.8%
ROA (Net income/ Total Assets) - -56.6% -37.3% -27.2% -14.9%
Assets 1 - 22.45 33.8 20.49 40.51
Book Value Per Share 2 141.0 102.0 125.0 112.0 25.30
Cash Flow per Share 2 141.0 115.0 127.0 129.0 29.70
Capex 1 0.01 0.01 0 0.01 0
Capex / Sales - - - - -
Announcement Date 3/30/21 3/30/21 3/29/22 3/21/23 4/1/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
SYNAPTOGENIX, INC. Stock Synaptogenix, Inc.
-28.80% 5.16M
MODERNA, INC. Stock Moderna, Inc.
+41.79% 50.93B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.56% 42.12B
LONZA GROUP AG Stock Lonza Group AG
+49.62% 42.05B
CELLTRION, INC. Stock Celltrion, Inc.
-7.20% 29.18B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.59% 26.02B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.51% 18.9B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+6.92% 13.21B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+24.91% 12.17B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.60% 12.16B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. SNPX Stock
  4. Financials Synaptogenix, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW